Multicenter comparison of glyburide and glipizide in the treatment of non-insulin-dependent diabetes mellitus.
A multicenter, randomized, open-label comparison of glyburide and glipizide was made in 109 patients with non-insulin-dependent diabetes mellitus whose fasting plasma glucose levels had been maintained at less than or equal to 140 mg/dl by tolbutamide, chlorpropamide, or glyburide. After an initial evaluation, patients entered a dose-adjustment phase to establish the optimal daily dose of the assigned drug--glyburide or glipizide--needed to maintain metabolic control. A second evaluation was made at the end of this phase. Patients then proceeded into the maintenance phase, which lasted approximately three months. A final evaluation was made upon completion of or withdrawal from the maintenance phase. Metabolic control was monitored by means of determinations of fasting plasma glucose and hemoglobin A1c. Comparative efficacy was assessed in relation to the doses of the respective drugs needed to maintain acceptable metabolic control. Safety was evaluated through reports of adverse effects as well as through laboratory tests and measurements of vital signs at each patient visit.